Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Ipca Labs entered a global licensing agreement with Bhami's Research Laboratory for its proprietary high-concentration subcutaneous biologics delivery platform. This partnership aims to develop and commercialize multiple monoclonal antibody products for oncology and inflammatory diseases, enhancing Ipca's biologics pipeline.
Jun 12 2026 17:26:52
Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Ipca Labs hosted its Q4 FY26 earnings conference call, where management reported an 8% increase in consolidated revenue to Rs.9,646 crore for FY26. The company also provided a positive outlook, guiding for a 12-13% consolidated growth for the current financial year.
Jun 04 2026 13:44:46
Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Change in Management
Ipca Laboratories' Board approved the re-appointment of Mr. Prashant Godha as Executive Director for a further five-year term, effective August 16, 2026. This re-appointment is subject to shareholder approval.
May 29 2026 13:59:48
Ipca Laboratories Ltd - 524494 - Board Meeting Outcome for Outcome Of Board Meeting
Ipca Laboratories board approved Q4 & FY26 financial results, with Q4 cons. net profit rising 341% YoY to ₹299.07 cr. The company also recommended a ₹6 dividend per share for FY26, setting August 7, 2026, as the record date.
May 29 2026 13:49:00
Read More